Optimized formulation of solid self-microemulsifying sirolimus delivery systems

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 1673-1682

  Cho, Wonkyung ^a,b   Kim, Min Soo ^c   Kim, Jeong Soo ^b   Park, Junsung ^a,b   Park, Hee Jun ^a,b   Cha, Kwang Ho ^a,b   Park, Jeong Sook ^b   Hwang, Sung Joo ^a  

^a Yonsei University   (South Korea)

^b Chungnam National University   (South Korea)

^c Inje University   (South Korea)

Author keywords

Bioavailability; Microemulsion; Self emulsifying drug delivery systems; Sirolimus; Solubility; Stability

Indexed keywords

RAPAMYCIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MICROEMULSION; NONHUMAN; PARTICLE SIZE; PROCESS OPTIMIZATION; RAT; STOMACH PH; TIME TO MAXIMUM PLASMA CONCENTRATION;

BIOAVAILABILITY; MICROEMULSION; SELF-EMULSIFYING DRUG DELIVERY SYSTEMS; SIROLIMUS; SOLUBILITY; STABILITY;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG STABILITY; EMULSIONS; GASTRIC JUICE; HYDROGEN-ION CONCENTRATION; MALE; MODELS, BIOLOGICAL; NANOPARTICLES; OILS; PARTICLE SIZE; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; SIROLIMUS; SOLUBILITY; SURFACE-ACTIVE AGENTS;

RATTUS;

EID: 84876858469     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S43299     Document Type: Article

References (27)

1. Vézina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo). 1975;28(10):721-726.
2. Martel RR, Klicius J, Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol. 1977;55(1):48-51.
3. Simamora P, Alvarez JM, Yalkowsky SH. Solubilization of rapamycin. Int J Pharm. 2001;213(1-2):25-29.
4. Rouf MA, Bilensoy E, Vural I, Hincal AA. Determination of stability of rapamycin following exposure to different conditions. Eur J Pharm Sci. 2007;32(1):S46-S46.
5. Luengo JI, Konialian AL, Holt DA. Studies on the chemistry of rapamycin: novel transformations under Lewis-acid catalysis. Tetrahedron Lett. 1993;34(6):991-994.
6. Steffan RJ, Kearney RM, Hu DC, et al. Base catalyzed degradations of rapamycin. Tetrahedron Lett. 1993;34(23):3699-3702.
7. Yohannes D, Myers CD, Danishefsky SJ. Degradation of rapamycin: synthesis of a rapamycin derived fragment containing the tricarbonyl and triene sectors. Tetrahedron Lett. 1993;34(13):2075-2078.
8. Vasquez EM. Sirolimus: a new agent for prevention of renal allograft rejection. Am J Health Syst Pharm. 2000;57(5):437-448.
9. Rosen H, Abribat T. The rise and rise of drug delivery. Nat Rev Drug Discov. 2005;4(5):381-385.
10. Shen LJ, Wu FLL. Nanomedicines in renal transplant rejection - focus on sirolimus. Int J Nanomedicine. 2007;2(1):25-32.
11. Alemdar AY, Sadi D, McAlister VC, Mendez I. Liposomal formulations of tacrolimus and rapamycin increase graft survival and fiber outgrowth of dopaminergic grafts. Cell Transplant. 2004;13(3):263-271.
12. Rouf M, Bilensoy E, Vural I, Hincal AA. Inclusion complexation of rapamycin with beta-cyclodextrin to improve solubility and stability of the drug. Eur J Pharm Sci. 2007;32(1):S46-S47.
13. Buech G, Bertelmann E, Pleyer U, Siebenbrodt I, Borchert HH. Formulation of sirolimus eye drops and corneal permeation studies. J Ocul Pharmacol Ther. 2007;23(3):292-303.
14. Preetham AC, Satish CS. Formulation of a poorly water-soluble drug sirolimus in solid dispersions to improve dissolution. J Dispers Sci Technol. 2011;32(6):778-783.
15. Kim MS, Kim JS, Park HJ, Cho WK, Cha KH, Hwang SJ. Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process. Int J Nanomedicine. 2011;6:2997-3009.
16. Balakrishnan P, Lee BJ, Oh DH, et al. Enhanced oral bioavailability of Coenzyme Q10 by self-emulsifying drug delivery systems. Int J Pharm. 2009;374(1-2):66-72.
17. Shah NH, Carvajal MT, Patel CI, Infeld MH, Malick AW. Self-emulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. Int J Pharm. 1994;106(1):15-23.
18. Kim CK, Cho YJ, Gao ZG. Preparation and evaluation of biphenyl dimethyl dicarboxylate microemulsions for oral delivery. J Control Release. 2001;70(1-2):149-155.
19. Prajapati BG, Patel MM. Conventional and alternative pharmaceutical methods to improve oral bioavailability of lipophilic drugs. Asian J Pharm. 2007;1(1):1-8.
20. Sun M, Si L, Zhai X, et al. The influence of co-solvents on the stability and bioavailability of rapamycin formulated in self-microemulsifying drug delivery systems. Drug Dev Ind Pharm. 2011;37(8):986-994.
21. Hu X, Lin C, Chen D, et al. Sirolimus solid self-microemulsifying pellets: formulation development, characterization and bioavailability evaluation. Int J Pharm. 2012;438(1-2):123-133.
22. Khoo S-M, Humberstone AJ, Porter CJH, Edwards GA, Charman WN. Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine. Int J Pharm. 1998;167(1-2):155-164.
23. Kommuru TR, Gurley B, Khan MA, Reddy IK. Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. Int J Pharm. 2001;212(2):233-246.
24. Craig DQM, Barker SA, Banning D, Booth SW. An investigation into the mechanisms of self-emulsification using particle-size analysis and low-frequency dielectric-spectroscopy. Int J Pharm. 1995; 114(1):103-110.
25. Constantinides PP. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm Res. 1995;12(11):1561-1572.
26. Carli F, Chiellini E, inventors; Remedia S.R.L., assignee. Pharmaceutical composition comprising a water/oil/water double microemulsion incorporated in a solid support. WO patent WO2003-013421. February 20, 2003.
27. Swenson ES, Curatolo WJ. Intestinal permeability enhancement for proteins, peptides and other polar drugs - mechanisms and potential toxicity 2. Adv Drug Deliv Rev. 1992;8(1):39-92.